PDS Biotechnology Corp is primarily active in the biotechnology industry.

Some of the main competitors of PDS Biotechnology Corp in the market include companies like Merck & Co., Inc., Bristol-Myers Squibb Company, and AstraZeneca PLC.

PDS Biotechnology Corp is a leading biotechnology company specializing in developing and commercializing novel immunotherapies for cancer and infectious diseases. Founded in 2005, the company has focused on its proprietary Versamune® platform technology, which activates the immune system for an effective response against various diseases. PDS Biotechnology Corp has conducted extensive research and clinical trials to demonstrate the potential of its platform in treating HPV-associated cancers, including cervical, head, and neck cancers. With its innovative approach and promising pipeline, PDS Biotechnology Corp is committed to advancing immunotherapies that have the potential to revolutionize the treatment landscape for patients worldwide.

PDS Biotechnology Corp has achieved significant milestones in its journey. The company has successfully developed Versamune®, a proprietary clinical-stage immunotherapy platform, which has shown promising results in preclinical and early clinical studies. PDS Biotechnology Corp has also made progress in its partnership with the National Cancer Institute (NCI) to advance cancer vaccines using its Versamune® platform. Additionally, the company has garnered attention for its involvement in the fight against HPV-associated cancers, including the initiation of a Phase 2 clinical trial for its lead candidate, PDS0101. Overall, PDS Biotechnology Corp continues to make important strides in developing innovative immunotherapies to address major medical challenges.

PDS Biotechnology Corp is primarily present in the United States.

PDS Biotechnology Corp represents a commitment to advancing healthcare through innovative biotechnological solutions. The company's corporate philosophy revolves around developing novel immunotherapies to effectively treat various types of cancer and infectious diseases. PDS Biotechnology Corp focuses on leveraging its proprietary Versamune® platform to create targeted therapies that enhance the immune system's ability to combat disease. This approach aligns with their ultimate goal of improving patient outcomes and quality of life. With a strong emphasis on research, clinical development, and collaboration with key industry stakeholders, PDS Biotechnology Corp strives to make a significant impact on the future of immunotherapy.

Analysts currently set an average price target of 7.65 USD for the PDS Biotechnology stock (median: 4.59 USD), implying +887.1 % versus the latest price. The consensus is based on 9 analyst ratings.

PDS Biotechnology Analyst Price Targets 2026

9 analysts currently rate the PDS Biotechnology stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect PDS Biotechnology to generate revenue of 11.25 M USD and earnings per share of -0.59 USD.

PDS Biotechnology Analyst Price Targets 2026

Converted at the current exchange rate, the PDS Biotechnology share trades at 0.67 EUR (0.77 USD).

The PDS Biotechnology share (PDSB) is listed on 4 stock exchanges, including: NASDAQ (PDSB), Frankfurt (EU6.F), München (EU6.MU), Düsseldorf (EU6.DU).

PDS Biotechnology Corp is a biopharmaceutical company specializing in the research and development of immunotherapeutic cancer treatments. The company utilizes a proprietary platform technology called Versamune® for the development of immunotherapeutics for treating various types of cancer. The business model of PDS Biotechnology Corp consists of two main divisions: research and product development, and strategic partnerships. The company's research and product development division focuses on developing immunotherapeutics based on Versamune®. This platform technology consists of a proprietary combination of molecules that activate the immune system and program it to specifically recognize and destroy cancer cells. The main product of PDS Biotechnology Corp currently is an immunotherapeutic called PDS0101, which was developed based on Versamune® and the PD-1 antigen. PDS0101 is currently in Phase 2 clinical development and is being tested for the treatment of HPV-associated cancer. The company also has other immunotherapeutics in the pipeline that have been developed based on Versamune® and could be used for the treatment of breast cancer, lung cancer, and other types of cancer. PDS Biotechnology Corp's strategic partnerships focus on collaborating with other companies and institutions to enhance access to resources and expertise. For example, the company is currently working with the National Cancer Institute to test its immunotherapeutics in clinical trials. In another collaboration, PDS Biotechnology Corp has entered into a partnership agreement with Farmacore Biotechnologia to develop and market its immunotherapeutics in Brazil and other Latin American countries. The business model of PDS Biotechnology Corp has the advantage of operating in a rapidly growing market. Immunotherapy has gained significant importance in recent years and offers a promising new approach to cancer treatment. This market is expected to continue growing in the coming years as more companies and research institutions invest in the development of immunotherapeutics. The company is also operating in a market segment that is traditionally dominated by large pharmaceutical companies. Most of the major pharmaceutical companies are currently investing substantial resources in immunotherapy development, creating intense competition. However, smaller companies like PDS Biotechnology Corp have the opportunity to focus on more specific indications and respond quickly to changes in market demand, as many of the large pharmaceutical companies are limited in the number of product candidates they can focus on. In summary, the business model of PDS Biotechnology Corp aims to develop innovative immunotherapeutics for cancer treatment while also building partnerships to improve access to resources and expertise. With its proprietary Versamune® platform technology and increasing presence in Latin America, the company has good growth prospects in a rapidly evolving market.

The expected revenue of PDS Biotechnology is 11.25 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of PDS Biotechnology is -27.23 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of PDS Biotechnology is currently -1.32. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the PDS Biotechnology stock.

The price-to-sales ratio (P/S) of PDS Biotechnology is currently 3.20. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the PDS Biotechnology stock.

The Eulerpool Quality Score for PDS Biotechnology is 2/10.

The ISIN of PDS Biotechnology is US70465T1079. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of PDS Biotechnology is A2PF3F. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of PDS Biotechnology is PDSB. The ticker symbol is used to trade PDS Biotechnology shares on the stock exchange.

PDS Biotechnology paid dividends every year for the past 0 years.

PDS Biotechnology is assigned to the 'Health' sector.

The dividends of PDS Biotechnology are distributed in USD.